Caroline Stewart

In a report published Friday, H.C. Wainwright & Co. analyst Caroline Stewart initiated a Neutral rating on Clovis Oncology (NASDAQ: CLVS) and set a price target of $55.00. In the report, H.C. Wainwright & Co. says "We believe that the current market valuation for CLVS fairly values: 1) CO-...